



Neuren (NEU) – ASX Announcement

28 February 2025

Neuren receives first DAYBUE™ sales milestone payment of US\$50 million

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) announced that it has today received in cash its first sales milestone payment that was due for the first calendar year in which net sales of DAYBUE™ (trofinetide) in North America exceed US\$250 million. Yesterday Neuren’s partner Acadia Pharmaceuticals reported 2024 net sales of DAYBUE in the United States of US\$348.4 million.

Neuren’s entitlement to sales milestone payments from commercialization of DAYBUE in North America is summarized in the table below.

Sales Milestones¹	
Net Sales in one calendar year	US\$m
≥US\$250m	✓ 50
≥US\$500m	50
≥US\$750m	100
≥US\$1bn	150

¹ Each sales milestone payment is payable once only.

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271



ASX Listing Rules information

This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.